Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 5, 2011, Pages 427-435

  Szczesniak, Anna Maria ^a   Maor, Yehoshua ^b   Robertson, Harold ^a   Hung, Orlando ^a,c   Kelly, Melanie E M ^a,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANABIGEROL DIMETHYLHEPTYL; CANNABIDIOL; CANNABINOID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; NONHUMAN; OCULOPLETHYSMOGRAPHY; RAT; TOPICAL TREATMENT;

ADMINISTRATION, OPHTHALMIC; ANIMALS; BENZOXAZINES; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; INTRAOCULAR PRESSURE; MORPHOLINES; NAPHTHALENES; RATS; RATS, INBRED BN; RECEPTORS, CANNABINOID; RESORCINOLS; TONOMETRY, OCULAR;

EID: 80054869394     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0041     Document Type: Article

References (77)

1. Di Marzo, V. The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol. Res. 60:77-84, 2009.
2. Bosier, B., Muccioli, G.G., Hermans, E., and Lambert, D.M. Functionally selective cannabinoid receptor signaling: Therapeutic implications and opportunities. Biochem. Pharmacol. 80:1-12, 2010.
3. Pertwee, R.G. The pharmacology of cannabinoid receptors and their ligands: An overview. Int. J. Obes. (Lond). 30(Suppl 1):S13-S18, 2006.
4. Di Marzo, V., Bifulco, M., and De Petrocellis, L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Disc. 3:771-784, 2004. (Pubitemid 39242829)
5. McIntosh, B.T., Hudson, B., Yegorova, S., Jollimore, C.A., and Kelly, M.E. Agonist-dependent cannabinoid receptor signaling in human trabecular meshwork cells. Br. J. Pharmacol. 152:1111-1120, 2007. (Pubitemid 350166054)
6. Lauckner, J.E., Hille, B., and Mackie, K. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl. Acad. Sci. U S A 102:19144-19149, 2005. (Pubitemid 43049580)
7. Hudson, B.D., Hèbert, T.E., and Kelly, M.E. Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors. Br. J. Pharmacol. 160:627-642, 2010.
8. Mackie, K. Cannabinoid receptors: Where they are and what they do. J. Neuroendocrinol. 20(Suppl 1):10-14, 2008. (Pubitemid 351552670)
9. Pertwee, R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol, and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 153:199-215, 2008.
10. Mackie, K., and Stella, N. Cannabinoid receptors and endocannabinoids: Evidence for new players. AAPS J. 8:E298-E306, 2006.
11. Offertá ler, L., Mo, F.M., Bátkai, S., et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol. 63:699-705, 2003. (Pubitemid 36297343)
12. Breivogel, C.S., Griffin, G., Di Marzo, V., and Martin, B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60:155-163, 2001. (Pubitemid 32595243)
13. Begg, M., Pacher, P., Batkai, S., et al. Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106:133-145, 2005. (Pubitemid 40613055)
14. Jarai, Z., Wagner, J.A., Varga, K., et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U S A 96:14136-14141, 1999.
15. Lambert, D.M., Vandevoorde, S., Jonsson, K.O., and Fowler, C.J. The palmitoylethanolamide family: A new class of antiinflammatory agents? Curr. Med. Chem. 9:663-674, 2002. (Pubitemid 34296196)
16. Hiley, C.R., and Kraup, S.S. GPR55 and the vascular receptors for cannabinoids. Br. J. Pharmacol. 152:559-561, 2007. (Pubitemid 350034976)
17. McHugh, D., Hu, S.S., Rimmerman, N., et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 11:44, 2010.
18. Bradshaw, H.B., Rimmerman, N., Hu, S.S., et al. The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochem. 10:14, 2009.
19. Zhang, X., Maor, Y., Wang, J.F., Kunos, G., and Groopman, J.E. Endocannabinoid-like N-arachidonolyl serine is a novel pro-angiogenic mediator. Br. J. Pharmacol. 160:1583-1594, 2010.
20. Nucci, C., Bari, M., Span, A., et al. Potential roles of (endo)cannabinoids in the treatment of glaucoma: From intraocular pressure control to neuroprotection. Prog. Brain Res. 173:451-464, 2008.
21. Jarvinen, T., Pate, D.W., and Laine, K. Cannabinoids in the treatment of glaucoma. Pharmacol. Ther. 95:203-220, 2002. (Pubitemid 35232138)
22. Tomida, I., Pertwee, R.G., and Azuara-Blanco, A. Cannabinoids and glaucoma. Br. J. Ophthalmol. 88:708-713, 2004. (Pubitemid 38526658)
23. Liu, J.H., and Dacus, A.C. Central nervous system and peripheral mechanisms in ocular hypotensive effect of cannabinoids. Arch. Ophthalmol. 105:245-248, 1987. (Pubitemid 17013707)
24. Stamer, W.D., Golightly, S.F., Hosohata, Y., et al. Cannabinoid CB1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur. J. Pharmacol. 431:277-286, 2001. (Pubitemid 33145404)
25. Porcella, A., Maxia, C., Gessa, G.L., and Pani, L. The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. Eur. J. Neurosc. 12:1123-1127, 2000. (Pubitemid 30168791)
26. Straiker, A.J., Maguire, G., Mackie, K., and Lindsey, J. Localization of the cannabinoid receptors in human anterior eye and retina. Invest. Ophthalmol. Vis. Sci. 40:2442-2448, 1999. (Pubitemid 29418406)
27. Pate, D.W., Jarvinen, K., Urtti, A., Mahadevan, V., and Jarvinen, T. Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci. 63:2181-2188, 1998. (Pubitemid 28545178)
28. Song, Z.H., and Slowey, C.A. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. J. Pharmacol. Exp. Ther. 292:136-139, 2000.
29. Szczesniak, A., Kelly, M., Whynot, S., Shek, P., and Hung, O. Ocular hypotensive effects of an intratracheally delivered liposomal delta9-tetrahydrocannabinol preparation in rats. J. Ocul. Pharmacol. Ther. 22:160-167, 2006. (Pubitemid 44051127)
30. Porcella, A., Maxia, C., Gessa, G.L., and Pani, L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur. J. Neurosci. 13:409-412, 2001. (Pubitemid 32142487)
31. Hosseini, A., Lattanzio, F.A., Williams, P.B., Tibbs, D., Samudre, S.S., and Allen, R.C. Chronic topical administration of WIN-55-212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects. Exp. Eye Res. 82: 753-759, 2006. (Pubitemid 43170876)
32. Oltmanns, M.H., Samudre, S.S., Castillo, I.G., et al. Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action. J. Ocul. Pharmacol. Ther. 24:104-115, 2008. (Pubitemid 351156637)
33. Nucci, C., Gasperi, V., Tartaglione, R., et al. Involvement of the endocannabinoid system in retinal damage after high intracellular pressure-induced ischemia in rats. Invest. Ophthalmol. Vis. Sci. 20048:2997-3004, 2008. (Pubitemid 351261139)
34. Baek, S.-H., Yook, C.N., and Han, D.S. Boron trifluoride etherate on alumina-A modified Lewis acid reagent(V) a convenient single-step synthesis of cannabinoids. Bull. Korean Chem. Soc. 16:293-296, 1995.
35. Maor, Y., et al. Cannabigerol-dimethyl heptyl (CBG-DMH), a synthetic cannabinoid with hypotensive and vasorelaxant properties. 2005 Symposium on the Cannabinoids. Burlington, VT: International Cannabinoid Research Society; 2005; Abstract 152.
36. Pan, J. Non-invasive measurement of intraocular pressure in the conscious rat with Tonopen tonometer. ARVO Inv. Opthalmol. Vis. Sci. 41:S897, 2000. Abstract 4771.
37. Baek, S.H.M., Srebnik, M., and Mechoulam, R. Borontrifluoride on alumina-a modified Lewis acid reagent. An improved synthesis of cannabidiol. Tetrahedron Lett. 26:1083-1086, 1985.
38. Sandeep, S.S., Schneider, J.L., Oltmanns, M.H., Hosseini, A., Pratap, K., Loose-Thurman, P., et al. Comparision of topical and intravenous administration of WIN55,212-2 in normotensive rabbits. Curr. Eye Res. 33:857-863, 2008.
39. Colasanti, B.K. A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol. J. Ocul. Pharmacol. 6:259-269, 1990.
40. Green, K., and Roth, M. Ocular effects of topical administration of delta 9-tetrahydrocannabinol in man. Arch. Ophthalmol. 100:265-267, 1982. (Pubitemid 12162233)
41. Martin, B.R., Compton, D.R., Prescott, W.R., Barrett, R.L., and Razdan, R.K. Pharmacological evaluation of dimethylheptyl analogs of delta 9-THC: Reassessment of the putative three-point cannabinoid-receptor interaction. Drug Alcohol Depend. 37:231-240, 1995.
42. Chien, F.Y.,Wang, R.F.,Mittag, T.W., and Podos, S.M. Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch. Ophthalmol. 121:87-90, 2003. (Pubitemid 36401772)
43. Hepler, R., and Frank, I. Marihuana smoking and intraocular pressure. JAMA 217:1392-1397, 1971.
44. Green, K., Cheeks, K., Bowman, K.A., Hodges, L.C., Deutsch, H.M., and Zalkow, L.H. Marihuana-derived material: Distribution and effects after systemic administration. Curr. Eye Res. 3:751-761, 1984. (Pubitemid 14138543)
45. Merritt, J.C., Crawford, W.J., Alexander, P.C., Anduze, A.L., and Gelbart, S.S. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 87:222-228, 1980. (Pubitemid 10130590)
46. Merritt, J.C., Perry, D.D., Russell, D.N., and Jones, B.F. Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J. Clin. Pharmacol. 21(8-9 Suppl):467S-471S, 1981.
47. Jay, W.M., and Green, K. Multiple-drop study of topically applied 1% delta 9-tetrahydrocannabinol in human eyes. Arch. Ophthalmol. 101:591-593, 1983. (Pubitemid 13116469)
48. Colasanti, B.K., Powell, S.R., and Craig, C. Intraocular pressure, ocular toxicity and neurotoxicity after administration of D9-tetrahydrocannabinol or cannabichromene. Exp. Eye Res. 38:63-71, 1984. (Pubitemid 14169734)
49. Laine, K., Jä rvinen, K., Mechoulam, R., Breuer, A., and Jä rvinen, T. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest. Ophthalmol. Vis. Sci. 43:3216-3222, 2002.
50. Laine, K., Jä rvinen, K., Pate, D.W., Urtti, A., and Jä rvinen, T. Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides. Invest. Ophthalmol. Vis. Sci. 43:393-397, 2002. (Pubitemid 34113220)
51. Porcella, A., Casellas, P., Gessa, G.L., and Pani, L. Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: Implications for the antiglaucoma properties of marihuana. Brain Res. Mol. Brain Res. 58:240-245, 1998. (Pubitemid 28352253)
52. Lu, Q., Straiker, A., Lu, Q., and Maguire, G. Expression of CB2 cannabinoid receptor mRNA in adult rat retina. Vis. Neurosci. 17:91-95, 2000. (Pubitemid 30167557)
53. Laine, K., Jä rvinen, K., and Jä rvinen, T. Topically administered CB2-receptor agonist, JWH-133 does not decrease intraocular pressure (IOP) in normotensive rabbits. Life Sci. 72:837-842, 2003. (Pubitemid 35452639)
54. Green, K., Wynn, H., and Padgett, D. Effects of delta9- tetrahydrocannabinol on ocular blood flow and aqueous humor formation. Exp. Eye Res. 26:65-69, 1978. (Pubitemid 8256902)
55. Lograno, M.D., and Romano, M.R. Cannabinoid agonists induce contractile responses through Gi/o-dependent activation of phospholipase C in the bovine ciliary muscle. Eur. J. Pharmacol. 494:55-62, 2004. (Pubitemid 38759831)
56. Stumpff, F., Boxberger, M., Krauss, A., et al. Stimulation of cannabinoid (CB1) and prostanoid (EP2) receptors opens BKCa channels and relaxes ocular trabecular meshwork. Exp. Eye Res. 80:697-708, 2005. (Pubitemid 40602971)
57. Rosch, S., Ramer, R., Brune, K., and Hinz, B. R±methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells. J. Pharmacol. 316:1219-1228, 2006. (Pubitemid 43345297)
58. Weinberg, R.N., and Lindsay, J.D. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest. Ophthalmol. Vis. Sci. 43:716-722, 2002.
59. Zakrzeska, A., Schlicker, E., Baranowska, M., Kozlowska, H., Kwolek, G., and Mailnowska, B. A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anesthetized rats. Br. J. Pharmacol. 160:574-584, 2010.
60. Ho, W.S., and Hiley, C.R. Vasodilator actions of abnormalcannabidiol in rat isolated small mesenteric artery. Br. J. Pharmacol. 138:1320-1332, 2003. (Pubitemid 36543130)
61. Kozlowska, H., Baranowska, M., Schlicker, E., Kozlowski, M., Laudań ski, J., and Malinowska, B. Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery. J. Hypertens. 25:2240-2248, 2007. (Pubitemid 47537917)
62. McHugh, D., Hu, S.S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J.M., and Bradshaw, H.B. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 26:44, 2010.
63. Song, Z.-H. Abnormal cannadidiol-induced increase in aqueous humor outflow. Assoc. Res. Vis. Ophthalmol. 2010; Abstract 145/A318.
64. Howlett, A.C., Champion, T.M., Wilken, G.H., and Mechoulam, R. Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology 29:161-165, 1990. (Pubitemid 20059592)
65. Beilin, M., Neumann, R., Belkin, M., Green, K., and Bar-Ilan, A. Pharmacology of the intraocular pressure (IOP) lowering effect of systemic dexanabinol (HU-211), a non-psychotropic cannabinoid. J. Ocular Pharmacol. 16:217-230, 2000. (Pubitemid 30366283)
66. Green, K., and Kim, K. Mediation of ocular tetrahydrocannabinol effects by adrenergic nervous system. Exp. Eye Res. 23:443-448, 1976.
67. Kobelt-Nguyen, G., Gerdtham, U.G., and Alm, A. Costs of treating primary open-angle glaucoma and ocular hypertension: A retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J. Glaucoma 7:95-104, 1998. (Pubitemid 28196096)
68. Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 42:327-360, 2003. (Pubitemid 36433875)
69. Yazulla, S. Endocannabinoids in the retina: From marijuana to neuroprotection. Prog. Retin. Eye Res. 27:501-526, 2008.
70. El Remessy, A.B., Khalil, I.E., Matragoon, S., et al. Neuroprotective effects of delta(9)-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspirate- induced retinal neurotoxicity; involvement of peroxynitrite. Am. J. Pathol. 63:1997-2008, 2003. (Pubitemid 37310030)
71. Opere, C.A., Zheng, W.D., Zhao, M., Lee, J.S., Kulkarni, K.H., and Ohia, S.E. Inhibition of potassium-and ischemiaevoked [3H] D-aspartate release from isolated bovine retina by cannabinoids. Curr. Eye Res. 31:645-653, 2006. (Pubitemid 44179991)
72. Crandall, J., Matragoon, S., Khalifa, Y.M., et al. Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in rat model of glaucoma. Opthalmic Res. 36:69-75, 2007. (Pubitemid 46909862)
73. Naveh, N., Weissman, C., Muchtar, S., Benita, S., and Mechulam, R. A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefes Arch. Clin. Exp. Ophthalmol. 238:334-338, 2000. (Pubitemid 30258928)
74. Schwartz, M., and Yoles, E. Optic nerve degeneration and potential neuroprotection: Implications for glaucoma. Eur. J. Ophthalmol. 9(Suppl1):S9-S11, 1999. (Pubitemid 29179928)
75. Yoles, E., Belkin, M., and Schwartz, M. HU-211, a nonpsychotropic cannabinoid produces short-and long-term neuroprotection after optic nerve axotomy. J. Neurotrauma 13:49-57, 1996. (Pubitemid 26069547)
76. Szczesniak, A.M. Neuroprotective and Anti-Neuroinflammatory Effects of the Nonpyschotropic, Atypical Cannabinoid, Abnormal Cannabidiol, in the Rat Retina. Montreal, Quebec: International Society for Eye Research; 2010.
77. Kreutz, S., Koch, M., Bö ttger, C., Ghadban, C., Korf, H.W., and Dehghani, F. 2-Arachidonylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol- sensitive receptors on microglia cells. Glia 57:286-294, 2009.